While cell-based immunotherapies have had remarkable success in the treatment of hematologic malignancies, these strategies have had limited efficacy in patients with solid tumors. To better understand the challenges hindering progress in the field, NCI is holding the 2nd NCI Workshop on Cell-Based Immunotherapy for Solid Tumors to engage in an interactive dialogue with extramural researchers.
Following up on the 1st NCI Workshop on Cell-Based Immunotherapy for Solid Tumors held in December 2018, this virtual meeting will review current efforts in the development of autologous and allogeneic cell-based therapies for solid tumors, including cutting-edge technologies for designing, testing, and manufacturing cell therapies. The goal of the meeting is to identify knowledge gaps, resource needs, and critical barriers in the field, providing the basis for NCI to better support the extramural community and accelerate progress toward the treatment of solid tumors.
Crystal L. Mackall, MD
Marcela V. Maus, MD, PhD
(Harvard University and Massachusetts General Hospital)
For information on NCI resources for cell therapy production, see Manufacturing Support.